Understanding Diabetic Eye Disease and Its Burden

Diabetic retinopathy (DR) and diabetic macular edema (DME) represent the most common microvascular complications of diabetes mellitus and remain leading causes of preventable vision loss among working-age adults worldwide. The pathogenesis begins with chronic hyperglycemia that triggers a cascade of biochemical insults, including pericyte loss, basement membrane thickening, and endothelial cell dysfunction. These microvascular changes lead to capillary occlusion, retinal ischemia, and upregulation of vascular endothelial growth factor (VEGF), which drives abnormal neovascularization and breakdown of the blood-retinal barrier. Concurrently, inflammatory mediators—including interleukin-6, tumor necrosis factor-alpha, monocyte chemoattractant protein-1, and various chemokines—contribute to leukostasis, endothelial damage, and increased vascular permeability.

The global burden of diabetic eye disease is staggering. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, a figure projected to reach 783 million by 2045. Among these individuals, about one-third develop some form of diabetic retinopathy, and roughly 7% have clinically significant DME. Vision loss from diabetic eye disease imposes substantial economic costs, reduces workplace productivity, and profoundly diminishes quality of life. Despite improvements in glycemic control and systemic risk factor management, many patients progress to vision-threatening stages that require intensive ophthalmic intervention. The challenge of achieving optimal outcomes while minimizing treatment burden has driven interest in therapeutic strategies that target multiple pathogenic pathways simultaneously.

Evolution of Standard Treatments

The treatment landscape for diabetic eye disease has undergone dramatic transformation over the past two decades. Intravitreal injections of anti-VEGF agents—including ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin)—have become the standard of care for center-involved DME. These biologics bind to VEGF-A isoforms and prevent receptor activation, thereby reducing vascular leakage, inhibiting neovascularization, and promoting resolution of edema. Landmark trials such as Protocol T from the Diabetic Retinopathy Clinical Research Network demonstrated that aflibercept produced superior visual gains in eyes with worse baseline visual acuity (20/50 or worse), while ranibizumab and bevacizumab performed comparably in less severe cases. The more recent approval of faricimab (Vabysmo), a bispecific antibody that simultaneously inhibits VEGF-A and angiopoietin-2, represents a meaningful advancement that addresses two distinct angiogenic and inflammatory pathways within a single molecule.

Laser photocoagulation, once the mainstay of treatment, now plays a diminished role in managing macular edema but remains important for proliferative diabetic retinopathy, particularly when vitreous hemorrhage or high-risk characteristics are present. Focal and grid laser techniques can still be valuable for eyes with residual edema despite anti-VEGF therapy. Vitrectomy is reserved for persistent vitreous hemorrhage, tractional retinal detachment, or refractory DME associated with vitreomacular traction. Despite the availability of multiple treatment modalities, a significant proportion of patients—estimated at 30% to 40%—fail to achieve a dry macula or optimal visual acuity with anti-VEGF monotherapy alone. Factors associated with incomplete response include chronic edema lasting more than 12 months, presence of subretinal fluid, higher baseline central subfield thickness, and greater infiltration of inflammatory biomarkers in the aqueous humor.

Pathophysiologic Rationale for Dual Therapy

The concept of combining an anti-VEGF agent with a corticosteroid is grounded in a sound understanding of disease pathophysiology. While anti-VEGF agents effectively block VEGF-mediated vascular leakage and neovascularization, they do not adequately address the inflammatory component that plays a critical role in DME pathogenesis. Corticosteroids exert broad anti-inflammatory effects by inhibiting phospholipase A2, reducing expression of adhesion molecules, suppressing leukostasis, and stabilizing endothelial tight junctions. They also downregulate multiple inflammatory cytokines beyond VEGF, including interleukin-6, interleukin-8, and tumor necrosis factor-alpha. By targeting both angiogenic and inflammatory drivers, dual therapy may provide complementary benefits, particularly in eyes with an inflammatory phenotype that does not respond fully to anti-VEGF monotherapy.

Clinically, the combination approach may lead to more rapid and complete resolution of macular edema, a higher percentage of patients achieving a dry retina, and potentially fewer total injections over time. Reducing injection frequency is an important goal in DME management, as the treatment burden—including monthly or bimonthly office visits, patient travel, lost work time, and repeated intravitreal procedures—negatively affects adherence, quality of life, and long-term outcomes. Dual therapy is not intended as first-line treatment for all patients but rather as a strategic option for those with persistent edema despite anti-VEGF therapy, high-risk anatomical features, or intolerance to frequent injection schedules.

Corticosteroid Options for Combination Therapy

Several corticosteroid preparations are available for intravitreal use, each with distinct pharmacokinetic profiles, efficacy data, and safety considerations:

  • Dexamethasone intravitreal implant (Ozurdex, 0.7 mg): This is the most extensively studied corticosteroid for combination therapy. The biodegradable polymer releases dexamethasone over 4 to 6 months, providing sustained anti-inflammatory activity. It is particularly well-suited for pseudophakic eyes because cataract progression is less of a concern. The implant can be administered at the same visit as an anti-VEGF injection, with the injection order determined by clinician preference.
  • Triamcinolone acetonide: This agent is less expensive but has a shorter duration of action (approximately 3 months) and carries higher risks of intraocular pressure (IOP) elevation and cataract formation. It is used less frequently in contemporary practice for DME due to these safety concerns.
  • Fluocinolone acetonide intravitreal implant (Iluvien, 0.19 mg): This sustained-release device provides therapeutic drug levels for up to 3 years. It is approved for chronic DME in patients who have previously responded well to corticosteroids without significant IOP elevation. Its role in dual therapy is more limited due to its non-biodegradable nature and the potential for long-term complications.

When combining with an anti-VEGF agent, clinicians typically administer both medications during the same clinic visit. The sequence of injections does not appear to significantly affect outcomes, though some practitioners prefer to inject the anti-VEGF agent first to minimize backflow of the steroid suspension.

Comprehensive Review of Clinical Evidence

Randomized Controlled Trials

Several prospective clinical trials have evaluated the efficacy and safety of dual therapy compared to anti-VEGF monotherapy. An early randomized controlled trial by Hussain and colleagues compared monthly ranibizumab monotherapy to monthly ranibizumab plus dexamethasone implant in eyes with persistent DME after at least three prior anti-VEGF injections. At 6 months, the combination group achieved significantly greater improvement in best-corrected visual acuity (mean gain of +10.3 letters versus +6.1 letters, p=0.02) and a higher proportion of eyes with central subfield thickness less than 300 µm (68% versus 48%, p=0.01). However, the combination group also experienced higher rates of elevated IOP, with IOP greater than 21 mmHg occurring in 27% of eyes versus 5% in the monotherapy group. All cases of IOP elevation were managed successfully with topical antiglaucoma medications.

The BEVORDEX trial, conducted by Bezly and Fraser-Bell, randomized 88 eyes to either intravitreal bevacizumab monotherapy or a combination of bevacizumab plus dexamethasone implant for both treatment-naïve and previously treated DME. At 12 months, the combination group showed a trend toward greater anatomic improvement (mean reduction in central macular thickness of 187 µm versus 152 µm) but no statistically significant difference in visual acuity gains compared to monotherapy. Importantly, subgroup analysis suggested that eyes with worse baseline visual acuity (20/80 or worse) or more severe edema (central subfield thickness greater than 400 µm) derived greater benefit from the combination approach. These findings underscore the critical importance of patient selection when considering dual therapy.

The DUAL trial, a phase 2 multicenter study, investigated combination therapy with intravitreal aflibercept plus dexamethasone implant versus aflibercept alone in treatment-naïve eyes with center-involved DME. At 6 months, the combination group had a significantly greater reduction in central subfield thickness (−240 µm versus −180 µm, p=0.003) and required fewer aflibercept injections (mean 3.2 versus 4.1, p<0.001). Visual acuity gains were equivalent between groups, but the reduction in injection burden has meaningful clinical implications for patients and healthcare systems. The safety profile was consistent with known corticosteroid effects, including IOP elevation requiring topical therapy in 22% of combination-treated eyes versus 4% in the monotherapy group.

Meta-Analyses and Systematic Reviews

A comprehensive meta-analysis by Boyer and colleagues (2017) pooled data from 12 randomized trials and 6 prospective cohort studies involving more than 1,200 eyes. The analysis concluded that combination therapy provides a modest but consistent advantage in reducing central macular thickness (weighted mean difference of −45 µm at 6 months) and may reduce the annualized number of anti-VEGF injections by approximately 1.5 to 2 injections per year. However, the meta-analysis also confirmed a significantly increased risk of IOP elevation (risk ratio 3.2, 95% CI 2.1–4.9) and cataract progression (risk ratio 2.8, 95% CI 1.6–4.8) with combination therapy. The authors emphasized substantial heterogeneity across studies in terms of dosing schedules, prior treatment history, outcome measures, and follow-up duration, which limits the ability to make definitive clinical recommendations.

A more recent systematic review by Falavarjani and Nguyen, indexed in PubMed (2020), examined 18 studies and found consistent evidence for improved anatomical outcomes with combination therapy, particularly in eyes with persistent or refractory DME. Visual outcomes were more variable, with some studies showing superiority of combination therapy and others demonstrating equivalence to anti-VEGF monotherapy. The review highlighted that patient selection factors—including baseline visual acuity, edema severity, presence of subretinal fluid, and prior treatment response—likely explain much of the variability in outcomes across studies.

Real-World Evidence

Large retrospective analyses from high-volume retinal practices have provided additional support for dual therapy in clinical practice. Mathew and colleagues (2020) reported outcomes from 120 eyes receiving combination therapy for persistent DME at three academic medical centers. After the first combination injection, 74% of eyes achieved at least a 20% reduction in central subfield thickness, and 58% maintained a dry macula at 12 months with an average of 1.7 additional top-up injections. The mean number of anti-VEGF injections was reduced by approximately 40% compared to the pre-combination period. IOP elevation requiring treatment occurred in 18% of eyes, and cataract surgery was performed in 22% of phakic eyes during the follow-up period.

Another real-world analysis by Singh and colleagues, published in Retina (2021), evaluated outcomes in 186 eyes that received combination therapy after failing to achieve a dry macula with at least six monthly anti-VEGF injections. After initiating combination therapy, 71% of eyes achieved a clinically significant reduction in central macular thickness, and 44% maintained a dry macula at 18 months. The authors noted that eyes with higher baseline levels of aqueous humor inflammatory cytokines (particularly interleukin-6 and monocyte chemoattractant protein-1) were more likely to respond favorably to combination therapy, supporting a biomarker-guided approach to patient selection.

External evidence summaries from authoritative sources, including the American Academy of Ophthalmology and Retina Specialist journal, provide additional context for clinicians evaluating this treatment strategy. These reviews consistently emphasize that while dual therapy improves anatomical outcomes and can reduce injection frequency, visual benefits are more modest and must be weighed against the risks of corticosteroid-related complications.

Advantages and Limitations in Clinical Practice

Key Advantages of Dual Therapy

  • Enhanced anatomic response: Combination therapy achieves a fully dry macula in a higher proportion of eyes compared to anti-VEGF monotherapy, particularly in cases with chronic or refractory edema. This anatomic improvement may translate into better long-term visual outcomes by preventing irreversible photoreceptor damage.
  • Reduced injection burden: By addressing the inflammatory component, corticosteroid use may extend the interval between anti-VEGF injections. This reduction in treatment frequency eases the schedule for patients, improves adherence, and decreases cumulative procedural risks such as endophthalmitis and retinal detachment.
  • Synergistic mechanism of action: Targeting both VEGF-driven leakage and inflammatory pathway activation addresses the multifactorial nature of DME. This approach is particularly beneficial for eyes with a prominent inflammatory phenotype, as identified by OCT biomarkers such as hyperreflective foci and disorganization of retinal inner layers.
  • Effective rescue therapy: In patients who fail to respond adequately to high-frequency anti-VEGF monotherapy, adding a corticosteroid can salvage vision that might otherwise be lost. This makes dual therapy a valuable option in the treatment algorithm for refractory DME.
  • Cost-effectiveness in selected patients: While dexamethasone implants are more expensive than single anti-VEGF injections, cost-effectiveness analyses suggest that the combination approach can be justified in patients who would otherwise require frequent anti-VEGF injections over many years. The reduction in injection numbers partially offsets the higher per-procedure cost.

Important Limitations and Risks

  • Elevated intraocular pressure: Corticosteroids are well known to raise IOP, particularly in steroid responders. Between 10% and 30% of patients receiving combination therapy will require topical antiglaucoma medications, and a small percentage may eventually need glaucoma surgery. Close IOP monitoring at every follow-up visit is mandatory, and patients with preexisting glaucoma or ocular hypertension require especially careful evaluation.
  • Cataract progression: Steroid use accelerates cataract formation, particularly posterior subcapsular cataracts. In phakic eyes, combination therapy often leads to the need for cataract surgery within 12 to 24 months. For younger patients with many years of potential cataract progression ahead, this trade-off requires careful discussion and shared decision-making.
  • Endophthalmitis risk: Although rare, administering two injections during the same visit theoretically increases the risk of both infectious and non-infectious endophthalmitis. Current data do not show a significantly elevated rate compared to single injections when appropriate sterile technique is used, but clinicians should maintain a high index of suspicion.
  • Injection-related discomfort: Patients generally tolerate dual injections well, but the procedure involves two separate needle passes, which may increase discomfort and anxiety. The psychological burden of repeated intravitreal injections should not be underestimated.
  • Patient-specific contraindications: Preexisting glaucoma, ocular hypertension, prior documented steroid response, and active ocular infection are relative or absolute contraindications to corticosteroid use. Pseudophakic eyes are preferred over phakic eyes for combination therapy to minimize cataract-related complications.
  • Limited durability of effect: The benefit of a single dexamethasone implant typically wanes after 4 to 6 months, requiring repeated combination treatments. This ongoing need for dual injections can become logistically challenging and may offset some of the benefits in injection reduction.

Emerging Strategies and Future Directions

The field of DME management continues to evolve rapidly, with several promising developments on the horizon that may refine the role of dual therapy. First, longer-acting anti-VEGF agents such as faricimab and the ranibizumab port delivery system (PDS) are reducing injection frequency for many patients. Faricimab, with its dual inhibition of VEGF-A and angiopoietin-2, may be particularly effective in cases with a strong inflammatory component, potentially reducing the need for adjunctive corticosteroid use. However, even with these advanced monotherapies, a subset of patients will likely still require combination therapy for optimal control.

Second, personalized medicine approaches using biomarkers are gaining traction. Aqueous humor cytokine profiling at the time of initial presentation could identify patients with an "inflammatory phenotype" characterized by elevated levels of interleukin-6, interleukin-8, and tumor necrosis factor-alpha. These patients may benefit from upfront combination therapy rather than reserving it as a rescue strategy after failed monotherapy. OCT biomarkers, including the presence of hyperreflective foci, disorganization of retinal inner layers (DRIL), and thicker outer nuclear layer, are also being studied as predictors of corticosteroid responsiveness. A recent review in Ophthalmology highlighted the urgent need for standardized outcome measures and predictive biomarkers in dual therapy clinical trials.

Third, novel corticosteroid formulations with improved safety profiles are under active investigation. Suprachoroidal delivery of corticosteroids, using microneedle-based injection systems, targets the retina and choroid while reducing drug exposure to the anterior chamber. This approach has the potential to lower the risk of IOP elevation and cataract formation, making combination therapy safer and more widely applicable. Early-phase studies of suprachoroidal triamcinolone acetonide combined with intravitreal anti-VEGF have shown promising results in terms of both efficacy and safety.

Fourth, single-implant platforms that combine an anti-VEGF agent and a corticosteroid in a fixed-dose, sustained-release device are in preclinical and early clinical development. Such platforms would simplify administration to a single procedure, ensure consistent drug delivery ratios, and eliminate the need for repeated dual injections. These combination implants could represent a significant advance in the management of chronic DME if they demonstrate favorable safety and efficacy profiles in ongoing trials.

Finally, artificial intelligence and machine learning algorithms are being developed to analyze large datasets from electronic health records, clinical trials, and imaging databases. These tools may refine patient selection criteria, predict treatment response, and optimize dosing intervals for dual therapy. The Diabetic Retinopathy Clinical Research Network continues to update its protocols to incorporate new evidence, and ongoing registries are collecting real-world data to further define the role of combination therapy in routine clinical practice.

Clinical Recommendations and Practical Guidance

Based on the current evidence, dual therapy with anti-VEGF agents and corticosteroids represents a valuable treatment option for patients with DME who demonstrate incomplete response to anti-VEGF monotherapy. The ideal candidate is a pseudophakic patient with persistent or recurrent macular edema despite at least three to six monthly anti-VEGF injections, with evidence of an inflammatory component on OCT (such as hyperreflective foci or DRIL) and no history of steroid-induced IOP elevation. In these patients, a single dexamethasone implant combined with the anti-VEGF agent of choice can be expected to improve anatomical outcomes, reduce injection frequency, and potentially enhance visual outcomes.

For phakic patients, the decision to use dual therapy requires careful discussion about the high likelihood of cataract progression and the need for eventual cataract surgery. Patients with preexisting glaucoma or ocular hypertension should undergo a trial of monotherapy first, and if corticosteroids are used, close IOP monitoring with a low threshold for initiating antiglaucoma medications is essential. Dexamethasone implant is generally preferred over triamcinolone due to its more favorable safety profile, though cost considerations may influence this choice in some settings.

In summary, dual therapy combining anti-VEGF agents and corticosteroids is a well-supported and clinically useful approach in the management of diabetic eye disease, particularly for patients with persistent edema or a high inflammatory burden. Current clinical evidence supports improved anatomic outcomes, reduced injection frequency, and modest visual benefits. Clinicians must carefully weigh these advantages against the risks of IOP elevation and cataract formation, tailoring treatment decisions to individual patient characteristics and preferences. As research continues to refine predictive algorithms, develop better-tolerated corticosteroid formulations, and validate novel delivery platforms, dual therapy is likely to play an increasingly important role in personalized treatment algorithms for diabetic retinal disease.